This informal session with a brief presentation followed by discussion will focus on opportunities in the biotech and pharma sector for non-dilutive capital. The SBIR program is a great way to kick-start research or a fund an innovative idea, yet moving beyond $1M, thinking about a commercialization strategy, building a business, and acquiring capital takes a bit of strategy. Accessing funds from the US Government, patient advocacy groups, charities such as the Wellcome Trust and the Gates Foundation, as well as social entrepreneurs has benefits for start-ups and established companies alike. These organizations provide capital, expertise, in-kind services, access to key opinion leaders, and more, in addition to complementing any traditional investment that may be required. The program also will introduce early key steps in establishing your business to protect yourself, grow, and to prepare to raise capital.
We look forward to discussing some of these options and ideas and working through any questions participants may have.
April 28th, 2017
Robert Paine Scripps Forum for Science, Society, and the Environment at Scripps Institution of Oceanography
Please RSVP here: https://goo.gl/forms/Ip1WSeCd7ifuf3w42
Note: Parking is street parking only. Cars in Scripps Oceanography lots without a UCSD AND Scripps permits will be ticketed.
4-5PM Presentation & Discussion, Robert Scripps Room
5-8PM Networking and Scripp TGIF social with Dentons and Tiber Creek Partners, Surfside
About the speakers:
Jennifer Schneider, PhD, MPH is a founding Principal of Tiber Creek Partners, LLC, a US-based boutique consultancy advising life science companies in sourcing non-traditional capital, developing strategic partnerships, and creating scientific messaging. Along with her business partners, she has helped to secure over $5 billion in capital for her clients in the past 10 years.
Phillip Bradley is Senior Counsel with the international law firm Dentons. Over his almost forty years of practice, Phil has served as General Counsel for three companies, including a start-up, a large retail pharmacy chain, and a publicly held national health care company. Phil's practice currently is focused on representing portfolio companies for private equity firms.